WOLVERINE ASSET MANAGEMENT LLC - THERAVANCE BIOPHARMA INC ownership

THERAVANCE BIOPHARMA INC's ticker is and the CUSIP is 88339KAA0. A total of 25 filers reported holding THERAVANCE BIOPHARMA INC in Q4 2019. The put-call ratio across all filers is - and the average weighting 0.4%.

Quarter-by-quarter ownership
WOLVERINE ASSET MANAGEMENT LLC ownership history of THERAVANCE BIOPHARMA INC
ValueSharesWeighting
Q2 2021$1,414,000
-93.3%
1,500,000
-92.7%
0.01%
-93.8%
Q1 2021$20,968,000
-8.1%
20,600,000
-14.5%
0.18%
+5.4%
Q4 2020$22,817,000
+7.2%
24,100,0000.0%0.17%
-11.1%
Q3 2020$21,294,000
-9.3%
24,100,0000.0%0.19%
-19.9%
Q2 2020$23,476,000
-1.0%
24,100,0000.0%0.24%
-31.4%
Q1 2020$23,717,000
-5.1%
24,100,0000.0%0.34%
+18.6%
Q4 2019$24,989,000
+11.6%
24,100,0000.0%0.29%
+2.1%
Q3 2019$22,397,000
+7.0%
24,100,0000.0%0.28%
+4.0%
Q2 2019$20,926,000
-10.8%
24,100,0000.0%0.27%
-14.7%
Q1 2019$23,451,000
-5.3%
24,100,0000.0%0.32%
+7.7%
Q4 2018$24,760,000
-13.3%
24,100,0000.0%0.30%
-10.5%
Q3 2018$28,543,000
+20.0%
24,100,0000.0%0.33%
+7.8%
Q2 2018$23,789,000
-2.8%
24,100,0000.0%0.31%
-2.8%
Q1 2018$24,481,000
-7.4%
24,100,0000.0%0.32%
+18.7%
Q4 2017$26,424,000
-10.2%
24,100,000
+0.3%
0.27%
-18.1%
Q3 2017$29,431,000
-9.3%
24,020,0000.0%0.33%
-20.9%
Q2 2017$32,436,000
+21.7%
24,020,000
+14.4%
0.41%
-0.5%
Q1 2017$26,657,000
+10.2%
21,000,0000.0%0.41%
+32.7%
Q4 2016$24,181,00021,000,0000.31%
Other shareholders
THERAVANCE BIOPHARMA INC shareholders Q4 2019
NameSharesValueWeighting ↓
Context Capital Management, LLC 6,000,000$5,827,0003.55%
DeepCurrents Investment Group LLC 21,223,000$20,803,0001.80%
ZAZOVE ASSOCIATES LLC 19,230,000$18,725,0001.77%
Mohican Financial Management, LLC 500,000$494,0001.61%
Castle Creek Arbitrage, LLC 5,149,000$5,015,0001.47%
LINDEN ADVISORS LP 62,688,000$61,071,0001.40%
Verition Fund Management LLC 10,817,000$10,504,0000.41%
WOLVERINE ASSET MANAGEMENT LLC 24,100,000$23,451,0000.32%
Baupost Group 30,000,000$29,213,0000.24%
SSI INVESTMENT MANAGEMENT LLC 2,763,000$2,676,0000.22%
View complete list of THERAVANCE BIOPHARMA INC shareholders